These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 2637935)

  • 1. MPTP-induced Parkinson-like disease in sheep: clinical and pathologic findings.
    Beale AM; Higgins RJ; Work TM; Bailey CS; Smith MO; Shinka T; Hammock BD
    J Environ Pathol Toxicol Oncol; 1989 Dec; 9(5-6):417-28. PubMed ID: 2637935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
    Nishi K; Kondo T; Narabayashi H
    No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys.
    Miletich RS; Bankiewicz KS; Quarantelli M; Plunkett RJ; Frank J; Kopin IJ; Di Chiro G
    Ann Neurol; 1994 Jun; 35(6):689-97. PubMed ID: 8210225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.
    Forno LS; Langston JW; DeLanney LE; Irwin I; Ricaurte GA
    Ann Neurol; 1986 Oct; 20(4):449-55. PubMed ID: 3024555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice.
    Bezard E; Dovero S; Bioulac B; Gross C
    Exp Neurol; 1997 Nov; 148(1):288-92. PubMed ID: 9398471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intrathecal infusion of brain-derived neurotrophic factor protects nigral dopaminergic neurons from degenerative changes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced monkey parkinsonian model].
    Takeda M
    Hokkaido Igaku Zasshi; 1995 Nov; 70(6):829-38. PubMed ID: 8582706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery.
    Mounayar S; Boulet S; Tandé D; Jan C; Pessiglione M; Hirsch EC; Féger J; Savasta M; François C; Tremblay L
    Brain; 2007 Nov; 130(Pt 11):2898-914. PubMed ID: 17855373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sympathetic innervation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease.
    Goldstein DS; Li ST; Holmes C; Bankiewicz K
    J Pharmacol Exp Ther; 2003 Sep; 306(3):855-60. PubMed ID: 12805479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of the central noradrenergic system in MPTP-induced monkey parkinsonism.
    Miyoshi R; Kito S; Ishida H; Katayama S
    Res Commun Chem Pathol Pharmacol; 1988 Oct; 62(1):93-102. PubMed ID: 2849789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity.
    D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH
    Nature; 1987 May 28-Jun 3; 327(6120):324-6. PubMed ID: 2884568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MPTP-Induced pallidal lesions in rhesus monkeys.
    Zhang Z; Zhang M; Ai Y; Avison C; Gash DM
    Exp Neurol; 1999 Jan; 155(1):140-9. PubMed ID: 9918713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of MPTP toxicity.
    Przedborski S; Jackson-Lewis V
    Mov Disord; 1998; 13 Suppl 1():35-8. PubMed ID: 9613716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MPTP: a pharmacological tool to study parkinsonism.
    Kulkarni SK; Mehta AK; Aley KO; Shukla VK
    Methods Find Exp Clin Pharmacol; 1986 Aug; 8(8):485-9. PubMed ID: 3489146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.
    Gibrat C; Saint-Pierre M; Bousquet M; Lévesque D; Rouillard C; Cicchetti F
    J Neurochem; 2009 Jun; 109(5):1469-82. PubMed ID: 19457163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease.
    Prediger RD; Rial D; Medeiros R; Figueiredo CP; Doty RL; Takahashi RN
    Ann N Y Acad Sci; 2009 Jul; 1170():629-36. PubMed ID: 19686204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
    C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Yasuda Y; Shinagawa R; Yamada M; Mori T; Tateishi N; Fujita S
    Brain Res; 2007 Mar; 1138():196-202. PubMed ID: 17275793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical mechanisms underlying MPTP-induced and idiopathic parkinsonism. New vistas.
    Singer TP; Ramsay RR; Sonsalla PK; Nicklas WJ; Heikkila RE
    Adv Neurol; 1993; 60():300-5. PubMed ID: 8380523
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.